{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:25:41Z","timestamp":1793420741884,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.tjpad.2025.100202","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T23:33:58Z","timestamp":1748043238000},"page":"100202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease"],"prefix":"10.1016","volume":"12","author":[{"given":"Jackson","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly M.","family":"Brothers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Matthew","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gersham","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioacchino","family":"Curiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tjpad.2025.100202_bib0001","article-title":"An insider's perspective on FDA approval of aducanumab","volume":"9","author":"Wang","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100202_bib0002","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100202_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100202_bib0004","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100202_bib0005","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/alz.12877","article-title":"Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid\/tau\/neurodegeneration framework (the Q-ATN model)","volume":"19","author":"Mazer","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100202_bib0006","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with alzheimer's disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100202_bib0007","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"7618","key":"10.1016\/j.tjpad.2025.100202_bib0008","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"7659","key":"10.1016\/j.tjpad.2025.100202_bib0009","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature22809","article-title":"Addendum: the antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"546","author":"Sevigny","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100202_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/psp4.12728","article-title":"Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease","volume":"11","author":"Kandadi Muralidharan","year":"2022","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100202_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100202_bib0012","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100202_bib0013","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: a systematic review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100202_bib0014","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.neurobiolaging.2022.02.012","article-title":"Development of prediction models for distinguishable cognitive trajectories in patients with amyloid positive mild cognitive impairment","volume":"114","author":"Kim","year":"2022","journal-title":"Neurobiol Aging"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100202_bib0015","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2174\/1567205017666201008105429","article-title":"Modelling decline in cognition to decline in function in alzheimer's disease","volume":"17","author":"Karcher","year":"2020","journal-title":"Curr Alzheimer Res"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100202_bib0016","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/s41593-024-01669-5","article-title":"Apolipoprotein E in Alzheimer's disease trajectories and the next-generation clinical care pathway","volume":"27","author":"Narasimhan","year":"2024","journal-title":"Nat Neurosci"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100202_bib0017","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1002\/alz.13128","article-title":"APOE \u03b54\u2032s impact on response to amyloid therapies in early symptomatic Alzheimer's disease: analyses from multiple clinical trials","volume":"19","author":"Evans","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100202_bib0018","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/alz.13431","article-title":"Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease","volume":"20","author":"Pang","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100202_bib0019","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","article-title":"APOE4 homozygosity represents a distinct genetic form of Alzheimer\u2019s disease","volume":"30","author":"Fortea","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100202_bib0020","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer's disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100202_bib0021","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/jnc.15023","article-title":"What works and what does not work in Alzheimer\u2019s disease? From interventions on risk factors to anti-amyloid trials","volume":"155","author":"Bullain","year":"2020","journal-title":"J Neurochem"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100202_bib0022","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1002\/alz.14134","article-title":"Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer's disease","volume":"20","author":"Raket","year":"2024","journal-title":"Alzheimer's Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725001463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725001463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:01:50Z","timestamp":1786482110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725001463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2274580725001463"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100202","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100202"}}